Here are the 10-Q quarterly reports from CARGO Therapeutics, Inc. (CRGX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CRGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRGX filings page.
Key highlights (Q2 2025, unaudited): CARGO Therapeutics reported combined cash and marketable securities of $252.6 million and total assets of $258.6 million as of June 30, 2025. The company recorded a six‑month net loss of $134.435 million, including $83.378 million of restructuring, impairment and contract‑termination charges. Accumulated deficit was $447.1 million and total stockholders' equity was $237.7 million.
Management implemented major workforce reductions (≈50% in Jan 2025; additional actions in Mar 2025 reducing workforce by ~90% overall), discontinued the Phase 2 firi‑cel program, impaired most long‑lived assets (carried to zero except $0.5M expected sale), incurred a lease termination penalty of $35.8 million, and recorded related impairments and contract termination costs. On July 7, 2025 the company entered into a Merger Agreement with Concentra providing a $4.379 cash per‑share offer plus one CVR. The company states existing cash and securities are sufficient to support operations for at least 12 months from issuance.